RT Journal Article
T1 Predicting response and survival in chemotherapy-treated triple-negative breast cancer.
A1 Prat, A
A1 Lluch, A
A1 Albanell, J
A1 Barry, W T
A1 Fan, C
A1 Chacón, J I
A1 Parker, J S
A1 Calvo, L
A1 Plazaola, A
A1 Arcusa, A
A1 Seguí-Palmer, M A
A1 Burgues, O
A1 Ribelles, N
A1 Rodriguez-Lescure, A
A1 Guerrero, A
A1 Ruiz-Borrego, M
A1 Munarriz, B
A1 López, J A
A1 Adamo, B
A1 Cheang, M C U
A1 Li, Y
A1 Hu, Z
A1 Gulley, M L
A1 Vidal, M J
A1 Pitcher, B N
A1 Liu, M C
A1 Citron, M L
A1 Ellis, M J
A1 Mardis, E
A1 Vickery, T
A1 Hudis, C A
A1 Winer, E P
A1 Carey, L A
A1 Caballero, R
A1 Carrasco, E
A1 Martín, M
A1 Perou, C M
A1 Alba, E
K1 Breast Cancer
K1 Genomics
K1 Subtypes
K1 Intrisic
K1 Basal Like
K1 Chemotherapy
K1 Neoadjuvant
K1 Resultado del tratamiento
K1 Neoplasias de la mama triple negativas
K1 Antineoplásicos
K1 Análisis de supervivencia
AB BACKGROUNDIn this study, we evaluated the ability of gene expression profiles to predict chemotherapy response and survival in triple-negative breast cancer (TNBC).METHODSGene expression and clinical-pathological data were evaluated in five independent cohorts, including three randomised clinical trials for a total of 1055 patients with TNBC, basal-like disease (BLBC) or both. Previously defined intrinsic molecular subtype and a proliferation signature were determined and tested. Each signature was tested using multivariable logistic regression models (for pCR (pathological complete response)) and Cox models (for survival). Within TNBC, interactions between each signature and the basal-like subtype (vs other subtypes) for predicting either pCR or survival were investigated.RESULTSWithin TNBC, all intrinsic subtypes were identified but BLBC predominated (55-81%). Significant associations between genomic signatures and response and survival after chemotherapy were only identified within BLBC and not within TNBC as a whole. In particular, high expression of a previously identified proliferation signature, or low expression of the luminal A signature, was found independently associated with pCR and improved survival following chemotherapy across different cohorts. Significant interaction tests were only obtained between each signature and the BLBC subtype for prediction of chemotherapy response or survival.CONCLUSIONSThe proliferation signature predicts response and improved survival after chemotherapy, but only within BLBC. This highlights the clinical implications of TNBC heterogeneity, and suggests that future clinical trials focused on this phenotypic subtype should consider stratifying patients as having BLBC or not.
PB Nature
SN 0007-0920
YR 2014
FD 2014-10-14
LK http://hdl.handle.net/10668/2031
UL http://hdl.handle.net/10668/2031
LA en
NO Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, et al. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br. J. Cancer. 2014; 111(8):1532-41
NO This work was presented, in part, as an oral communication at the ASCO 2012 annual meeting (Abstract #10500). Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 5, 2025